Stockscreener 앱 받기
42.33
0.55%
0.23
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
Congress Asset Management Co. Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Rice Hall James & Associates LLC Raises Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Will MoonLake Immunotherapeutics Lead Healthcare Stocks’ Resurgence? - DSA
Why MoonLake Immunotherapeutics Could Be the Next Big Bet in Healthcare - MotoPaddock
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Yahoo Finance
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
(MLTX) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for MLTX FY2025 Earnings? - MarketBeat
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely - Yahoo Finance
Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Has $62,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
(MLTX) Trading Report - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Swiss company MoonLake leverages Cambridge in transformative year - Business Weekly
When the Price of (MLTX) Talks, People Listen - Stock Traders Daily
Cantor Fitzgerald Estimates MLTX FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on MLTX FY2025 Earnings - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 6.3%Still a Buy? - MarketBeat
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpWhat's Next? - MarketBeat
MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN
This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat
MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat
MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks
MLTX Crosses Below Key Moving Average Level - Nasdaq
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Yahoo Finance
MoonLake initiates three new clinical trials and further - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Finansavisen
0.27%
3.05%
자본화:
|
볼륨(24시간):